Replies to post #41429 on OncoSec Medical Inc (ONCSQ)

[Titan V]

Weren’t the majority of ONCS p2b patients biomarker-predicted non-responders, although a good fraction were indeed actual anti-PD1 failures?

[Waitforit53]

Yeah, Adam doesn't get too far into the specifics to hedge against conclusions at early phase development, but with regards the comparison of Epacadostat to ImmunoPulse, those distincetions your pointing out are forcasting a greater success rate -- BUT also, ImmunoPulses squeeky clean safety profile of only mild grade one adverse events, comparitively:

The latest update reported 17% of patients suffered grade three or worse treatment-related adverse events. That compares favorably to results generated by Bristol-Myers’ combination, which, in an update earlier this year, was linked to a 58% rate of grade three or four adverse events.

17% of patients report Grade 3 and up, meaning Severe, life-threatening AE's, to include death.